VL is a blood-born parasitic disease that afflicts 12 million people worldwide, mainly in developing countries and tropical regions. According to the World Health Organization, 1.5 million new cases of the disease are reported every year, and 60,000 people die from it.

AmB, a 50-year-old anti-fungal drug, is the standard treatment for VL, but its current formulation requires intravenous administration and constant refrigeration, making it costly and challenging to deliver in tropical regions, where VL takes the heaviest toll, said the researchers.

A lipid-based formulation, co-developed by UBC Pharmaceutical Sciences Professor Kishor Wasan and Adjunct Professor Ellen Wasan, allows the drug to be taken orally. It was licensed to Vancouver-based iCo Therapeutics in 2008.

As part of the licensing agreement, and in accordance with UBC’s Global Access principles, iCo Therapeutics agrees to provide the drug at subsidized costs to developing countries for the treatment of VL.

“In most places where VL is a problem, there is little infrastructure for refrigeration of drug products,” says Kishor Wasan, co-author of the study. “Now we’ve shown for the first time this lipid-based formulation can stand up to the harsh conditions of the tropical climate and is effective in animal models when taken orally.”

“The development of this thermally stable and efficacious oral formulation brings us one step closer to helping people in remote areas of India, Bangladesh, Nepal and Sudan, where VL is a serious problem,” says Ellen Wasan, lead author of the PLoS-NTD paper.

Have your say and discuss with your peers on the InfoGrok community.